| PurposeThe aim of this study was to investigate the expression of E selectin and its ligand sLex in nasopharyngeal primary cancer and metastatic nasopharyngeal carcinoma (NPC), including cervical lymph node metastatic cancer and distant organ metastatic cancer, and to explore the relationship between their expression and clinical characteristics.Materials and methods1 Specimen source:82 blocks are collected which came from patiants dignosed as nasopharyngeal carcinoma between January 2012 and October 2013 in Affiliated Tumor Hospital of Guangxi Medical University, of which 36 blocks originated from metastasis carcinoma tissues, and 46 blocks originated from primary carcinoma tissues.30 blocks were collected as control group,which were diagnosed as chronic inflammatory nasopharyngeal mucosa with nasopharyngeal epithelial tissue. The primary carcinoma were diagnosed as nasopharyngeal carcinoma by pathological examination, and metastasis of carcinoma was confirmed by pathology and Clinical stage,which was according to UICC2010 staging criteria.2. The experimental group:four groups were set up, the primary cancer group, the paracancer group, the control group, the metastasis cancer group. The primary cancer group was further divided into primary cancer group with metastasis and primary carcinoma group without metastasis; metastasis group was further divided into lymph node metastasis group and hematogenous metastasis group according to the transfer mode. The paracarcinima group was non cancerous nasopharyngeal epithelium next to nasopharyngeal carcinoma, and the control group was diagnosed as nasopharyngeal mucosa epithelium with chronic inflammation by pathological diagnosis. According to the tumor 2010UICC TNM staging criteria, primary cancers were divided into T1-T2 and T3,T4 three groups which indicatated the size of tumor, and four groups from No to N3, which tells the statement of lymph metastasis, and M0、M1 two groups which tells the distinct metastasis.3. The expression of selectin and the ligand sleX in primary nasopharyngeal carcinoma and paracancerous tissues and control tissue, lymph node metastasis of nasopharyngeal carcinoma, and distant organ metastasis carcinoma was detected by SABC immunohistochemistry method. The relationship between the expression and the clinical features of nasopharyngeal carcinoma was analyzed by the combination of the experimental results with the pathological and clinical data.Result1. Expression positive rate of E-selectin in primary nasopharyngeal carcinoma and paracarcinoma group and control group were 67.4% (31/46),24.3% (9/ 37) and 17.7% (5/30), there is a statasis difference between primary nasopharyngeal carcinoma and paracancerous group, as well as between primary nasopharyngeal carcinoma and control group (P< 0.01, P< 0.01)2. Expression positive rate of sleX in primary nasopharyngeal carcinoma and para carcinoma group and control group was 63.04%(29/46),21.6%(8/37) and 13.3% (4/30), indicating that primary nasopharyngeal carcinoma and paracancer group is compared by significant difference, primary nasopharyngeal carcinoma and control group is compared by significant difference (P< 0.01, P< 0.01)3. Expression positive rate of E selectin in 36 cases of metastatic carcinoma,29 primary carcinoma tissues with metastasis and the control tissues were 72.7% (26/36),93.1% (27/29),17.7% (5/30), three groups compared with statistical difference,P<0.01; metastatic carcinoma and primary cancer with metastasis have a significant difference, P<0.01; expression between metastatic carcinoma and control group and expression between the primary cancer and control group both showed significant difference (P< 0.01).4. The positive rates of sleX in 36 metastasis carcinoma tissues,29 primary carcinnoma tissues with metastasis and 30 tissues of control group were 80.1% (29/36),82.8%(24/29),13.3%(4/30) respectively. Among the three groups, metastasis group and control group had statistical difference (P< 0.01), primary carcinoma with metastasis group and the control group were compared with significant difference (P<0.01) and comprison between metastasis group and primary carcinoma with metastasis group showed no statistical difference (P> 0.05).5. The positive rates of E selectin in 17 cases of primary carcinoma without metastases and 30 cases in control group were 23.5% (4/17),17.7% (5/30), and no significant difference showed between the two groups (P>0.05).6. The positive rate of sleX in the primary cancer tissues with no metastasis was 29.4% (4/17) and no significant difference compared with the control group 13.3%(4/30) (P>0.05).7. The positive expression rate of E-selectin in distant metastasis and lymph metastasis carcinoma group was 77.8% (7/9),70.3% (19/27), and there was no significant difference between the two groups (P>0.05).8. The positive rates of sleX in the metastatic carcinoma group and the lymph node metastasis group were 77.8% (7/9),81.4%, (22/27), and there was no significant difference between the two groups (P>0.05).9. There was signifficant statasis difference in expression of E-selectin between primary carcinoma without metastasis group,primary carcinoma with lymph nodes metastasis group and lymph nodes carcinoma, P<0.01; the expression with higher positive rate in primary carcinoma with lympha nodes metastases group have signifficant statasis difference with that in lympha metastasis group, P<0.01.10. There was signifficant statasis difference in expression of sleX between primary carcinoma without metastasis group, primary carcinoma with lymph nodes metastasis group and lymph nodes carcinoma, P<0.01;the expression in primary carcinoma with lympha nodes metastases shows no signifficant statasis difference with that in lympha metastasis group, P>0.05.11.In primary cancer with metastases group, the positive rate of E-selectin was 93.1%; in primary cancer without metastasis, positive rate was 23.5%, the expression of two groups has statistical significance, P< 0.01; In primary cancer with distant metastasis group,positive rate was 91.7%, in primary cancer without distant metastasis, positive rate was 58.8%; expression between the two group was statistically significant (P< 0.05). the positive expression rate of E-selectin in primary carcinoma with lymph node metastasis was No 23.5%, Ni in 100%, N2 93.8%,90% of stage N3, respectively, difference between the expression of groups was statistically significant (P< 0.05). Positive rate of E-selectin in primary cancer in each group respectively for stage Ⅰ-Ⅱ was 42.9%, stage Ⅲ was 63.6%,75.0% in stage Ⅳ and expression had no statistical significance (P> 0.05). T staging of the tumor in each group, the positive rate of T1-T2 was 61.5%,63.6% in T3 group, the T4 group was 72.7%. Among the groups expression had no statistical significance (P> 0.05).12.The positive rates of sleX in primary cancer with metastasis and without metastasis were 29.4% and 82.8%, and the expression of the two groups was statistically different, P<0.05. The positive rates of primary cancer patients with lymph node metastasis were 29.4% for No,100% for N1,68.8% for N2, 100% for N3, and sleX expression in each group were statistically significant, p<0.05. SLex in primary carcinoma with distant metastasis group the positive rate was 83.3%, in patients without distant metastasis of primary carcinoma, the positive rate was 55.9%, two groups compared with statistical significance, p<0.05; the positive rate of primary cancer clinical stage Ⅰ-Ⅱ was 28.6%, the positive rate of Ⅲ was 45%, the positive the rate of Ⅳ was 78.6%, the expression in primary carcinoma of clinical stage in each group have statistical significant difference, P<0.05; the positive expression rate in primary carcinoma of T stage were respectively T1-T2 38.5%, the positive rate of T3 was 63.6%, the positive rate of T4 was 77.3%, no statistical difference between groups (P>0.05), but there was signifficant statistical difference between T1-T2 and T3-T4,P<0.05; the positive rate of younger patiant was 56%, the positive rate of older than 50 years old group was 71.4%, there was no significant difference (P>0.05); gender groups, the positive rate of male group was 62.5%, the positive rate of female was 64.3% there was no significant difference (P>0.05).13.The positive expression rate of E-selectin in the metastasis cancer at the younger age was 70%, and the positive expression rate of the metastasis cancer at the older age was 75%, and the positive expression rate of the two groups was not significantly different, P>0.05. The positive expression rate of E-selectin in the male metastatic cancer group was 66.7%(14/21), and the the positive rate was 80%(12/15) in the female metastatic cancer group. There was no significant difference between the two groups, P>0.05.14. The positive rate of SleX in older group in metastasis carcinoma group was 78.9%(15/19); the positive expression rate in the younger group in metastases carcinoma group was 82.4%(14/17) between the two groups, there was not statistically significant difference (P> 0.05). The positive expression rate of sleX in the male metastatic carcinoma group was 81% (17/21), and the positive expression rate of the female group was 80% (12/15). There was no significant difference between the two groups, P>0.05.15.Correlation detection:there was a not bad correlationship between expression of E-selectin and sleX in primary carcinoma. And there was a bad correlationship between expression of sleX and E-selectin.Conclusion1. E-selectin and sleX were highly expressed in primary nasopharyngeal carcinoma and metastasis carcinoma, and were associated with the occurrence, developing and metastasis of NPC. Expression of E-selectin and sleX have no relationship with age and gender according to this research.2. The expression of E-selectin was not associated with the tumor T stage and clinical stage according to this research.3. The expression of sleX was related to tumor T staging, and was associated with tumor clinicals tage. sleX was associated with local invasion of NPC according to this research. |
PDF Full Text Request